
Photo from Jennifer Marks/X
Aug 24, 2024, 13:58
Jennifer Marks: The new NSCLC FDA Oncology approvals
Jennifer Marks, Thoracic Oncologist at Georgetown Lombardi, shared a post on X, referencing an earlier post from July 31st 2024:
“An updated version of the previous one given the new NSCLC FDA Oncology approvals: AEGEAN (perioperative durva plus chemo x 4 durva x 1 year) and MARIPOSA (1L ami plus lazer in mEGFR).”
Source: Jennifer Marks/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 11:36
Feb 21, 2025, 11:29
Feb 21, 2025, 10:45